Successful life settlement investing is influenced heavily by having a clear understanding of the insured’s life expectancy (LE). Almost all life settlement investors produce an LE during the initial policy due diligence process because it informs the bid—life settlements are valued via a discounted future cash flows basis, working backwards from the expected policy maturity date.
Insurers are favouring funded re as it helps firms manage the market and longevity risks associated with writing bulk purchase annuity (BPA) business by reducing capital charges and therefore making PRT deals more competitive.
Unsurprisingly, given its growth and potential for capital optimisation, UK regulators have been carefully watching the increased use of funded re. In June 2023, the Prudential Regulatory Authority (PRA) sent a “Dear CRO’ letter to heads of risk at UK life insurers.
The letter outlined the regulator’s two main concerns from a sectoral review which it had carried out.
“One of the key risks arising in funded re is that firms recapture sub-optimal portfolios with depressed values and with limited ability to be transformed effectively to the firms’ preferred portfolio,” the PRA letter said.
Related Posts
New Life Settlement Provider Data Illustrates Continued Evolution of Secondary Life Settlement Market
Life settlement market continuing growth trajectory despite overall reduction in life settlement provider licenses.
End-Game Clarity Shaping UK Pension Risk Transfer Market but Large Schemes Still on the Sidelines
Run-on options for schemes small and large set to become real consideration for UK defined…
Litigation Update: Estate of Martha Barotz v. Wilmington Savings Fund Society, FSB, et al.
A recent decision by the Delaware Court of Chancery brings some clarity to life settlement…
South Dakota Supreme Court Upholds Life Settlement Investor’s Right to Retain $10 Million Death Benefit
Decision is a significant positive development for investors in the life settlement industry as it…
